Skip to main content
Erschienen in:

27.04.2022

Quality of life after long-term biochemical control of acromegaly

verfasst von: Allison Kimball, Laura E. Dichtel, Kevin C. J. Yuen, Whitney W. Woodmansee, Melanie S. Haines, Lisa B. Nachtigall, Brooke Swearingen, Pamela Jones, Nicholas A. Tritos, Julie L. Sharpless, Ursula B. Kaiser, Anu Gerweck, Karen K. Miller

Erschienen in: Pituitary | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess long-term quality of life (QoL) in patients with sustained biochemical control of acromegaly, comparing those receiving vs not receiving pharmacotherapy (primary analysis); to assess change in QoL over time (secondary analysis).

Methods

Cross-sectional study, with a secondary longitudinal component, of 58 patients with biochemically controlled acromegaly. All had participated in studies assessing QoL years previously, after having undergone surgery ± radiotherapy. One cohort received medical therapy [MED (n = 33)]; the other did not [NO-MED (n = 25)]. QoL was assessed by the 36-Item-Short-Form Health Survey (SF-36), Acromegaly Quality of Life Questionnaire (AcroQoL), Gastrointestinal Quality of Life Index (GIQLI), Symptom Questionnaire, and QoL-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA).

Results

Mean (± SD) duration of biochemical control was 15.0 ± 6.4 years for MED and 20.4 ± 8.2 years for NO-MED (p = 0.007). 58% of subjects scored < 25% of normal on ≥ 1 SF-36 domain and 32% scored < 25% of normal on ≥ 4 of 8 domains. Comparing MED vs NO-MED and controlling for duration of biochemical control, there were no significant differences in QoL by SF-36, AcroQOL, GIQLI, Symptom Questionnaire, or QoL-AGHDA. Growth hormone deficiency (GHD) but not radiotherapy predicted poorer QoL. In MED, QoL improved over time in three AcroQoL domains and two GIQLI domains. In NO-MED, QoL worsened in two SF-36 domains and two Symptom Questionnaire domains; QoL-AGHDA scores also worsened in subjects with GHD.

Conclusion

A history of acromegaly and development of GHD, but not pharmacologic or radiotherapy, are detrimental to QoL, which remains poor over the long-term despite biochemical control.
Literatur
1.
Zurück zum Zitat Kyriakakis N, Lynch J, Gilbey SG, Webb SM, Murray RD (2017) Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: results from a 5-years prospective study. Clin Endocrinol 86(6):806–815CrossRef Kyriakakis N, Lynch J, Gilbey SG, Webb SM, Murray RD (2017) Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: results from a 5-years prospective study. Clin Endocrinol 86(6):806–815CrossRef
2.
Zurück zum Zitat Pantanetti P, Sonino N, Arnaldi G, Boscaro M (2002) Self image and quality of life in acromegaly. Pituitary 5(1):17–19CrossRefPubMed Pantanetti P, Sonino N, Arnaldi G, Boscaro M (2002) Self image and quality of life in acromegaly. Pituitary 5(1):17–19CrossRefPubMed
3.
Zurück zum Zitat Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM et al (2005) Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the acromegaly quality of life questionnaire (acroqol). Clin Endocrinol 63(1):103–110CrossRef Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM et al (2005) Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the acromegaly quality of life questionnaire (acroqol). Clin Endocrinol 63(1):103–110CrossRef
4.
Zurück zum Zitat Paisley AN, Rowles SV, Roberts ME, Webb SM, Badia X, Prieto L et al (2007) Treatment of acromegaly improves quality of life, measured by acroqol. Clin Endocrinol 67(3):358–362CrossRef Paisley AN, Rowles SV, Roberts ME, Webb SM, Badia X, Prieto L et al (2007) Treatment of acromegaly improves quality of life, measured by acroqol. Clin Endocrinol 67(3):358–362CrossRef
5.
Zurück zum Zitat Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P (2008) Impaired quality of life of patients with acromegaly: control of gh/igf-i excess improves psychological subscale appearance. Eur J Endocrinol 158(3):305–310CrossRefPubMed Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P (2008) Impaired quality of life of patients with acromegaly: control of gh/igf-i excess improves psychological subscale appearance. Eur J Endocrinol 158(3):305–310CrossRefPubMed
6.
Zurück zum Zitat Broersen LHA, Zamanipoor Najafabadi AH, Pereira AM, Dekkers OM, van Furth WR, Biermasz NR (2021) Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 106(2):577–587CrossRefPubMed Broersen LHA, Zamanipoor Najafabadi AH, Pereira AM, Dekkers OM, van Furth WR, Biermasz NR (2021) Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 106(2):577–587CrossRefPubMed
7.
Zurück zum Zitat Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW et al (2004) Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 89(11):5369–5376CrossRefPubMed Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW et al (2004) Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 89(11):5369–5376CrossRefPubMed
8.
Zurück zum Zitat Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F (2005) Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90(5):2731–2739CrossRefPubMed Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F (2005) Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90(5):2731–2739CrossRefPubMed
9.
Zurück zum Zitat Kauppinen-Makelin R, Sane T, Sintonen H, Markkanen H, Valimaki MJ, Loyttyniemi E et al (2006) Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab 91(10):3891–3896CrossRefPubMed Kauppinen-Makelin R, Sane T, Sintonen H, Markkanen H, Valimaki MJ, Loyttyniemi E et al (2006) Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab 91(10):3891–3896CrossRefPubMed
10.
Zurück zum Zitat Guo X, Wang K, Yu S, Gao L, Wang Z, Zhu H et al (2021) Quality of life and its determinants in patients with treated acromegaly: a cross-sectional nationwide study in china. J Clin Endocrinol Metab 106(1):211–225CrossRefPubMed Guo X, Wang K, Yu S, Gao L, Wang Z, Zhu H et al (2021) Quality of life and its determinants in patients with treated acromegaly: a cross-sectional nationwide study in china. J Clin Endocrinol Metab 106(1):211–225CrossRefPubMed
11.
Zurück zum Zitat Pelsma ICM, Biermasz NR, van Furth WR, Pereira AM, Kroon HM, Kloppenburg M et al (2021) Progression of acromegalic arthropathy in long-term controlled acromegaly patients: 9 years of longitudinal follow-up. J Clin Endocrinol Metab 106(1):188–200CrossRefPubMed Pelsma ICM, Biermasz NR, van Furth WR, Pereira AM, Kroon HM, Kloppenburg M et al (2021) Progression of acromegalic arthropathy in long-term controlled acromegaly patients: 9 years of longitudinal follow-up. J Clin Endocrinol Metab 106(1):188–200CrossRefPubMed
12.
Zurück zum Zitat van der Klaauw AA, Biermasz NR, Hoftijzer HC, Pereira AM, Romijn JA (2008) Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. Clin Endocrinol 69(1):123–128CrossRef van der Klaauw AA, Biermasz NR, Hoftijzer HC, Pereira AM, Romijn JA (2008) Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. Clin Endocrinol 69(1):123–128CrossRef
13.
Zurück zum Zitat Yoshida K, Fukuoka H, Matsumoto R, Bando H, Suda K, Nishizawa H et al (2015) The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the acroqol. Pituitary 18(6):876–883CrossRefPubMed Yoshida K, Fukuoka H, Matsumoto R, Bando H, Suda K, Nishizawa H et al (2015) The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the acroqol. Pituitary 18(6):876–883CrossRefPubMed
14.
Zurück zum Zitat Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ (2005) Quality of life (qol) in patients with acromegaly is severely impaired: use of a novel measure of qol: acromegaly quality of life questionnaire. J Clin Endocrinol Metab 90(6):3337–3341CrossRefPubMed Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ (2005) Quality of life (qol) in patients with acromegaly is severely impaired: use of a novel measure of qol: acromegaly quality of life questionnaire. J Clin Endocrinol Metab 90(6):3337–3341CrossRefPubMed
15.
Zurück zum Zitat Wexler T, Gunnell L, Omer Z, Kuhlthau K, Beauregard C, Graham G et al (2009) Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab 94(7):2471–2477CrossRefPubMedPubMedCentral Wexler T, Gunnell L, Omer Z, Kuhlthau K, Beauregard C, Graham G et al (2009) Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab 94(7):2471–2477CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Postma MR, Netea-Maier RT, van den Berg G, Homan J, Sluiter WJ, Wagenmakers MA et al (2012) Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. Eur J Endocrinol 166(4):585–592CrossRefPubMed Postma MR, Netea-Maier RT, van den Berg G, Homan J, Sluiter WJ, Wagenmakers MA et al (2012) Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. Eur J Endocrinol 166(4):585–592CrossRefPubMed
17.
Zurück zum Zitat Tseng FY, Chen ST, Chen JF, Huang TS, Lin JD, Wang PW et al (2019) Correlations of clinical parameters with quality of life in patients with acromegaly: Taiwan acromegaly registry. J Formos Med Assoc Taiwan yi zhi 118(11):1488–1493CrossRefPubMed Tseng FY, Chen ST, Chen JF, Huang TS, Lin JD, Wang PW et al (2019) Correlations of clinical parameters with quality of life in patients with acromegaly: Taiwan acromegaly registry. J Formos Med Assoc Taiwan yi zhi 118(11):1488–1493CrossRefPubMed
18.
Zurück zum Zitat Ghajar A, Jones PS, Guarda FJ, Faje A, Tritos NA, Miller KK et al (2020) Biochemical control in acromegaly with multimodality therapies: outcomes from a pituitary center and changes over time. J Clin Endocrinol Metab 105(3):e532CrossRef Ghajar A, Jones PS, Guarda FJ, Faje A, Tritos NA, Miller KK et al (2020) Biochemical control in acromegaly with multimodality therapies: outcomes from a pituitary center and changes over time. J Clin Endocrinol Metab 105(3):e532CrossRef
19.
Zurück zum Zitat Dichtel LE, Kimball A, Yuen KCJ, Woodmansee W, Haines MS, Guan QX et al (2021) Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly. Clin Endocrinol 94(1):58–65CrossRef Dichtel LE, Kimball A, Yuen KCJ, Woodmansee W, Haines MS, Guan QX et al (2021) Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly. Clin Endocrinol 94(1):58–65CrossRef
20.
Zurück zum Zitat McHorney CA, Ware JE Jr, Raczek AE (1993) The mos 36-item short-form health survey (sf-36): Ii. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31(3):247–263CrossRefPubMed McHorney CA, Ware JE Jr, Raczek AE (1993) The mos 36-item short-form health survey (sf-36): Ii. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31(3):247–263CrossRefPubMed
21.
Zurück zum Zitat Webb SM, Badia X, Surinach NL (2006) Validity and clinical applicability of the acromegaly quality of life questionnaire, acroqol: a 6-month prospective study. Eur J Endocrinol 155(2):269–277CrossRefPubMed Webb SM, Badia X, Surinach NL (2006) Validity and clinical applicability of the acromegaly quality of life questionnaire, acroqol: a 6-month prospective study. Eur J Endocrinol 155(2):269–277CrossRefPubMed
22.
Zurück zum Zitat Eypasch E, Williams JI, Wood-Dauphinee S, Ure BM, Schmulling C, Neugebauer E et al (1995) Gastrointestinal quality of life index: development, validation and application of a new instrument. Br J Surg 82(2):216–222CrossRefPubMed Eypasch E, Williams JI, Wood-Dauphinee S, Ure BM, Schmulling C, Neugebauer E et al (1995) Gastrointestinal quality of life index: development, validation and application of a new instrument. Br J Surg 82(2):216–222CrossRefPubMed
23.
Zurück zum Zitat Kellner R (1987) A symptom questionnaire. J Clin Psychiatry 48(7):268–274PubMed Kellner R (1987) A symptom questionnaire. J Clin Psychiatry 48(7):268–274PubMed
24.
Zurück zum Zitat McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L et al (1999) The qol-aghda: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 8(4):373–383CrossRefPubMed McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L et al (1999) The qol-aghda: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 8(4):373–383CrossRefPubMed
25.
Zurück zum Zitat Arshad MF, Ogunleye O, Ross R, Debono M (2021) Surgically treated acromegaly patients have a similar quality of life whether controlled by surgery or requiring additional medical therapy (qualat study). Pituitary 24(5):768–777CrossRefPubMedPubMedCentral Arshad MF, Ogunleye O, Ross R, Debono M (2021) Surgically treated acromegaly patients have a similar quality of life whether controlled by surgery or requiring additional medical therapy (qualat study). Pituitary 24(5):768–777CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Miller KK, Wexler T, Fazeli P, Gunnell L, Graham GJ, Beauregard C et al (2010) Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab 95(2):567–577CrossRefPubMedPubMedCentral Miller KK, Wexler T, Fazeli P, Gunnell L, Graham GJ, Beauregard C et al (2010) Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab 95(2):567–577CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Feldt-Rasmussen U, Abs R, Bengtsson BA, Bennmarker H, Bramnert M, Hernberg-Ståhl E et al (2002) Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or cushing’s disease. Eur J Endocrinol 146(1):67–74CrossRefPubMed Feldt-Rasmussen U, Abs R, Bengtsson BA, Bennmarker H, Bramnert M, Hernberg-Ståhl E et al (2002) Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or cushing’s disease. Eur J Endocrinol 146(1):67–74CrossRefPubMed
28.
Zurück zum Zitat Winther KH, Cramon P, Watt T, Bjorner JB, Ekholm O, Feldt-Rasmussen U et al (2016) Disease-specific as well as generic quality of life is widely impacted in autoimmune hypothyroidism and improves during the first six months of levothyroxine therapy. PLoS ONE 11(6):e0156925CrossRefPubMedPubMedCentral Winther KH, Cramon P, Watt T, Bjorner JB, Ekholm O, Feldt-Rasmussen U et al (2016) Disease-specific as well as generic quality of life is widely impacted in autoimmune hypothyroidism and improves during the first six months of levothyroxine therapy. PLoS ONE 11(6):e0156925CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Tan NC, Chew RQ, Subramanian RC, Sankari U, Koh YLE, Cho LW (2019) Patients on levothyroxine replacement in the community: association between hypothyroidism symptoms, co-morbidities and their quality of life. Fam Pract 36(3):269–275CrossRefPubMed Tan NC, Chew RQ, Subramanian RC, Sankari U, Koh YLE, Cho LW (2019) Patients on levothyroxine replacement in the community: association between hypothyroidism symptoms, co-morbidities and their quality of life. Fam Pract 36(3):269–275CrossRefPubMed
30.
Zurück zum Zitat Samuels MH, Kolobova I, Niederhausen M, Janowsky JS, Schuff KG (2018) Effects of altering levothyroxine (l-t4) doses on quality of life, mood, and cognition in l-t4 treated subjects. J Clin Endocrinol Metab 103(5):1997–2008CrossRefPubMedPubMedCentral Samuels MH, Kolobova I, Niederhausen M, Janowsky JS, Schuff KG (2018) Effects of altering levothyroxine (l-t4) doses on quality of life, mood, and cognition in l-t4 treated subjects. J Clin Endocrinol Metab 103(5):1997–2008CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Wolters TLC, Roerink S, Sterenborg R, Wagenmakers M, Husson O, Smit JWA et al (2020) The effect of treatment on quality of life in patients with acromegaly: a prospective study. Eur J Endocrinol 182(3):319–331CrossRefPubMed Wolters TLC, Roerink S, Sterenborg R, Wagenmakers M, Husson O, Smit JWA et al (2020) The effect of treatment on quality of life in patients with acromegaly: a prospective study. Eur J Endocrinol 182(3):319–331CrossRefPubMed
Metadaten
Titel
Quality of life after long-term biochemical control of acromegaly
verfasst von
Allison Kimball
Laura E. Dichtel
Kevin C. J. Yuen
Whitney W. Woodmansee
Melanie S. Haines
Lisa B. Nachtigall
Brooke Swearingen
Pamela Jones
Nicholas A. Tritos
Julie L. Sharpless
Ursula B. Kaiser
Anu Gerweck
Karen K. Miller
Publikationsdatum
27.04.2022
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 3/2022
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-022-01224-0

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Metastasiertes CRC: besser Checkpointhemmer im Doppelpack!

Die Kombination von Nivolumab plus Ipilimumab ist beim metastasierten Kolorektalkarzinom mit MSI-H- oder dMMR klar im Vorteil gegenüber einer Nivolumab-Monotherapie: Das Progressionsrisiko war damit in einer Phase-3-Studie um 38% reduziert.

Riesenzellarteriitis: bilaterale Biopsie der Temporalarterien von Vorteil

Die Riesenzellarteriitis (RZA) erfordert eine rasche und präzise Diagnose, da innerhalb weniger Tage ein schwerer, irreversibler Sehverlust drohen kann. In diesem Zusammenhang scheint die bilaterale Biopsie der Temporalarterien (TAB) der unilateralen überlegen zu sein.

Große Trinkmengen bei Blasentumoren möglicherweise von Nachteil

Beim nicht-muskelinvasiven Blasenkrebs scheint eine hohe Flüssigkeitszufuhr keinen schützenden Effekt in Bezug auf das Risiko eines Rezidivs oder einer Krankheitsprogression zu haben. Eine niederländische Studie legt sogar nahe, dass große Trinkmengen das Fortschreiten der Erkrankung begünstigen könnten.

Höhere Trefferquoten bei Brustkrebsscreening dank KI?

Künstliche Intelligenz unterstützt bei der Auswertung von Mammografie-Screenings und senkt somit den Arbeitsaufwand für Radiologen. Wie wirken sich diese Technologien auf die Trefferquote und die Falsch-positiv-Rate aus? Das hat jetzt eine Studie aus Schweden untersucht.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.